Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115

We designed a trial using two sequential cycles of modified high-dose melphalan at 100 mg/m(2) and autologous SCT (mHDM/SCT) in AL amyloidosis (light-chain amyloidosis, AL), AL with myeloma (ALM) and host-based high-risk myeloma (hM) patients through SWOG-0115. The primary objective was to evaluate...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Sanchorawala, V, Hoering, A, Seldin, DC, Finn, KT, Fennessey, SA, Sexton, R, Mattar, B, Safah, HF, Holmberg, LA, Dean, RM, Orlowski, RZ, Barlogie, B
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2013
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3855173/
https://ncbi.nlm.nih.gov/pubmed/23852321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bmt.2013.98
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg